Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 4,980 matching trials from the live ClinicalTrials.gov search.

Filters: San Diego, California Clear all

Conditions: Advanced Liver Cancers
Interventions: Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 16
States / cities: Costa Mesa, California • Duarte, California • Orange, California + 11 more

Conditions: Advanced Malignant Solid Neoplasm, HIV Infection, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Interventions: Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 20
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 9 more

Conditions: Degenerative Disc Disease, Spinal Stenosis
Interventions: OssDsign® Catalyst; Device
Lead sponsor: OssDsign; Industry
Eligibility: 21 Years and older
Enrollment: 450 participants
Timeline: 2022 – 2030
U.S. locations: 16
States / cities: Fresno, California • Long Beach, California • San Diego, California + 13 more

Conditions: Schizophrenia
Interventions: SEP-363856; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 25
States / cities: Anaheim, California • Bellflower, California • Culver City, California + 19 more

Conditions: Major Depressive Disorder, Treatment Resistant Depression
Interventions: Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) -- Sham maintenance rTMS; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: San Diego, California • New York, New York

Conditions: Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions: Aripiprazole, OPC-14597; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: Cerritos, California • Garden Grove, California • San Diego, California + 8 more

Conditions: Pain, Chronic Pain, Back Pain, Nociceptive Pain, Neuropathic Pain, Musculoskeletal Pain, Neck Pain, Pain, Intractable
Interventions: Observational; Other
Lead sponsor: Proove Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 31
States / cities: Prescott, Arizona • Heber Springs, Arkansas • Beverly Hills, California + 24 more

Conditions: Coronary Artery Disease
Interventions: Cleerly Labs and Cleerly ISCHEMIA; Device
Lead sponsor: Cleerly, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Mobile, Alabama • Huntington Park, California • San Diego, California + 18 more

Conditions: Pre-Bronchiolitis Obliterans Syndrome
Interventions: ARINA-1, Standard of care only; Drug · Other
Lead sponsor: Renovion, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more

Conditions: Sexually Transmitted Infections, Gay, Pre Exposure Prophylaxis
Interventions: Quantitative survey, HIV and STI testing, Qualitative Assessment; Behavioral · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 675 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: San Diego, California • Atlanta, Georgia • Chicago, Illinois

Conditions: Spinal Disease, Degenerative Disc Disease
Interventions: OssiMend™ Bioactive Moldable; Device
Lead sponsor: Collagen Matrix; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Encinitas, California • Hartford, Connecticut • Somerset, New Jersey + 1 more

Conditions: Colon Cancer
Interventions: Mailed Educational Reminder; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 50 Years to 100 Years
Enrollment: 775 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: Oral Budesonide Suspension (OBS), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 11 Years to 55 Years
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 77
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 64 more

Conditions: Coronary Artery Disease, Coronary Stenosis, Atherosclerosis, STEMI, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)
Interventions: Coronary PCI guided by OCT, Coronary PCI guided by Angiography; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Burlingame, California + 37 more

Conditions: Neurocognitive Dysfunction
Interventions: Transseptal Aortic Approach Catheter Ablation Procedure, Retrograde Aortic Approach Catheter Ablation Procedure; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Depressive Disorder, Major
Interventions: Rapastinel; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 128
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 104 more

Conditions: Sedentary Lifestyle
Interventions: Physical Activity intervention; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Early-Onset Scoliosis Deformity of Spine
Interventions: MAGEC® Spinal Bracing And Distraction System; Device
Lead sponsor: Pediatric Spine Foundation; Other
Eligibility: 5 Years to 9 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more

Conditions: Hepatitis C
Interventions: ABT-493, ABT-530; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 20
States / cities: Dothan, Alabama • Bakersfield, California • Coronado, California + 14 more

Conditions: Melanoma
Interventions: Nilotinib, DTIC; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 14
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 11 more

Conditions: Pleural Effusion
Interventions: LTI-01, Placebo; Drug
Lead sponsor: Rein Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 33
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 27 more

Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Interventions: Azacitidine, Pevonedistat; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 23
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more

Conditions: Small Cell Lung Cancer
Interventions: Rovalpituzumab tesirine, Topotecan, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 31
States / cities: Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 28 more

Conditions: Cardiac Disease
Interventions: DEFINITY®; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 15
States / cities: Tucson, Arizona • Los Angeles, California • Orange, California + 12 more

Search by objective public record fields.

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

OssDsign® Spine Registry Study ("Propel")

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Maintenance rTMS for Depression (Maitr-De)

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management

A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

HIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men

OssiMend BA in Posterolateral Instrumented Lumbar Fusion

Impact of a Mailed Educational Reminder on Fecal Occult Blood Testing (FOBT): A Randomized Controlled Trial

A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved

ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)

Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

Physical Activity and Education Program for Somali Women

Hospital-Based Cluster Trial: Magnetically Controlled Growing Rods Using Distraction Intervals

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY